Shi Lili, Min Rong, Wu Yanyan, Liu Jiahui, Liu Xia, Wang Peichang
Xuanwu Hospital Capital Medical University, China.
J Int Med Res. 2025 Aug;53(8):3000605251362969. doi: 10.1177/03000605251362969. Epub 2025 Aug 4.
ObjectiveTo investigate the value of myositis-specific autoantibodies in the diagnosis of idiopathic inflammatory myopathy and tumor risk prediction in patients with clinically suspected idiopathic inflammatory myopathy.MethodsThis retrospective study analyzed the myositis-specific autoantibodies and clinical characteristics of 357 patients with clinically suspected idiopathic inflammatory myopathy. Statistical analyses were conducted to assess the associations between myositis-specific autoantibodies and clinical symptoms.ResultsAmong the 357 patients with suspected idiopathic inflammatory myopathy, the co-occurrence rate of anti-synthetase and anti-Ro52 was 52.63%. Univariate analysis demonstrated significantly higher diagnostic rates of idiopathic inflammatory myopathy in patients positive for anti-synthetase and anti-Ro52 than in those who were seronegative. Patients who tested positive for anti-signal recognition particle exhibited distinct serological profiles and diagnostic outcomes compared with those who tested negative. Significant associations were observed between myositis-specific autoantibodies and tumor biomarkers. Multivariate logistic regression analysis identified serum creatinine and anti-synthetase antibody positivity as independent diagnostic predictors of idiopathic inflammatory myopathy.DiscussionAnti-synthetase antibodies were independently associated with idiopathic inflammatory myopathy. Co-positivity for anti-synthetase and anti-Ro52 was closely related to the diagnosis of idiopathic inflammatory myopathy. Myositis antibodies were significantly correlated with tumor biomarkers, highlighting their potential utility in early cancer screening. Elevated serum creatinine was also independently associated with idiopathic inflammatory myopathy, exhibiting diagnostic significance.ConclusionMyositis-specific autoantibodies have potential clinical value for early tumor screening and the diagnosis of idiopathic inflammatory myopathy.
目的
探讨肌炎特异性自身抗体在特发性炎性肌病诊断及临床疑似特发性炎性肌病患者肿瘤风险预测中的价值。
方法
本回顾性研究分析了357例临床疑似特发性炎性肌病患者的肌炎特异性自身抗体及临床特征。进行统计分析以评估肌炎特异性自身抗体与临床症状之间的关联。
结果
在357例疑似特发性炎性肌病患者中,抗合成酶抗体与抗Ro52抗体的共出现率为52.63%。单因素分析显示,抗合成酶抗体和抗Ro52抗体阳性患者的特发性炎性肌病诊断率显著高于血清学阴性患者。抗信号识别颗粒抗体检测阳性的患者与检测阴性的患者相比,具有不同的血清学特征和诊断结果。观察到肌炎特异性自身抗体与肿瘤生物标志物之间存在显著关联。多因素逻辑回归分析确定血清肌酐和抗合成酶抗体阳性是特发性炎性肌病的独立诊断预测指标。
讨论
抗合成酶抗体与特发性炎性肌病独立相关。抗合成酶抗体和抗Ro52抗体同时阳性与特发性炎性肌病的诊断密切相关。肌炎抗体与肿瘤生物标志物显著相关,突出了其在早期癌症筛查中的潜在效用。血清肌酐升高也与特发性炎性肌病独立相关,具有诊断意义。
结论
肌炎特异性自身抗体在早期肿瘤筛查和特发性炎性肌病诊断中具有潜在的临床价值。